血清肿瘤标志物YKL-40与乳腺癌预后关系的研究  

Research of serum YKL-40 levels and prognosis in patients with breast cancer

作　　者：翟博[1] 胡凤丽[2] 姜争[1] 赵金鹏[1] 王东[1] 潘尚哈[3] 孙岩岩[1] 

机构地区：[1]哈尔滨医科大学附属第四医院普外科,黑龙江哈尔滨150001 [2]哈尔滨医科大学附属第四医院消化内科,黑龙江哈尔滨150001 [3]哈尔滨医科大学附属第一医院中心实验室,黑龙江哈尔滨150001

出　　处：《中国现代普通外科进展》2012年第4期266-268,280,共4页Chinese Journal of Current Advances in General Surgery

基　　金：黑龙江省教育厅科学技术研究(面上)项目(11551208)

摘　　要：目的:探讨血清YKL-40水平与乳腺癌预后相关因素的关系。方法:采用酶联免疫吸附试验测定乳腺癌患者(实验组)及健康者(对照组)各40例的血清YKL-40水平,比较YKL-40水平在不同年龄、肿瘤直径、淋巴结转移、病理类型及TNM分期患者间的差异。结果:乳腺癌患者血清YKL-40水平明显高于健康对照组(P<0.05)。肿瘤直径>2 cm患者YKL-40水平明显高于直径≤2 cm组患者(P<0.01)。淋巴结转移阳性患者血清YKL-40水平明显高于淋巴结转移阴性患者(P<0.05)。随着肿瘤TNM分期进展,血清YKL-40水平逐渐升高(P<0.01)。不同年龄及病理类型患者间血清YKL-40水平无明显差异。结论:血清YKL-40水平与乳腺癌预后相关,可望成为乳腺癌新的肿瘤标志物及治疗靶点。Objective： To investigate the value of serum YKL-40 in the prognosis of breast cancer.Methods： Enzyme-linked mimuunosorbent assay（ELISA） was used to measure serum levels of YKL-40 in 40 patients with breast cancer and 40 healthy females cntrols for medical examination.The differences of serum YKL-40 levels was compared in the parameters of age,tumor diameter,the amount of transferred lymph nodes,pathological type and TNM stage.Results： The serum YKL-40 levels in patients with breast cancer was higher than that in healthy female controls（P0.05）.Serum YKL-40 levels were also higher in patients with tumour size 2 cm（P0.05） and transferred lymph node（P0.01）.The serum YKL-40 levels increased with the advancement in TNM stage.The mean follow-up time was 4.5 years（range： 3~6 years）.The recurrence was seen in 3 patients,and two died of distant metastasis（one in brain,another in lung and liver）.Conclusion： The serum YKL-40 levels are correlative with progonosis of patients with breast cancer,and may be a promosing tumor marker and target for molecular targeted therapy.

关 键 词：乳腺肿瘤 人软骨糖蛋白39 预后 

分 类 号：R737.9[医药卫生—肿瘤]